HU228433B1 - Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules - Google Patents
Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules Download PDFInfo
- Publication number
- HU228433B1 HU228433B1 HU0003956A HUP0003956A HU228433B1 HU 228433 B1 HU228433 B1 HU 228433B1 HU 0003956 A HU0003956 A HU 0003956A HU P0003956 A HUP0003956 A HU P0003956A HU 228433 B1 HU228433 B1 HU 228433B1
- Authority
- HU
- Hungary
- Prior art keywords
- compounds
- target molecule
- compound
- diffusion
- dimensional
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title claims description 103
- 238000005481 NMR spectroscopy Methods 0.000 title description 8
- 150000001875 compounds Chemical class 0.000 claims description 153
- 238000001228 spectrum Methods 0.000 claims description 92
- 238000000034 method Methods 0.000 claims description 61
- 239000000203 mixture Substances 0.000 claims description 50
- 238000009792 diffusion process Methods 0.000 claims description 48
- 230000027455 binding Effects 0.000 claims description 30
- 230000008569 process Effects 0.000 claims description 15
- 238000012216 screening Methods 0.000 claims description 15
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 150000003384 small molecules Chemical class 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 238000004611 spectroscopical analysis Methods 0.000 claims description 7
- 230000008878 coupling Effects 0.000 claims description 5
- 238000010168 coupling process Methods 0.000 claims description 5
- 238000005859 coupling reaction Methods 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 claims description 2
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- YTAHJIFKAKIKAV-XNMGPUDCSA-N [(1R)-3-morpholin-4-yl-1-phenylpropyl] N-[(3S)-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepin-3-yl]carbamate Chemical compound O=C1[C@H](N=C(C2=C(N1)C=CC=C2)C1=CC=CC=C1)NC(O[C@H](CCN1CCOCC1)C1=CC=CC=C1)=O YTAHJIFKAKIKAV-XNMGPUDCSA-N 0.000 claims 2
- 230000004071 biological effect Effects 0.000 claims 1
- 230000004962 physiological condition Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 238000003556 assay Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 229910019142 PO4 Inorganic materials 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 8
- 239000010452 phosphate Substances 0.000 description 8
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 description 7
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 description 7
- 125000005647 linker group Chemical group 0.000 description 7
- 239000011550 stock solution Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000012938 design process Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000002605 large molecules Chemical class 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108700016256 Dihydropteroate synthases Proteins 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- 241000238413 Octopus Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000007824 aliphatic compounds Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000009146 cooperative binding Effects 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 235000019788 craving Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- -1 small molecule organic compounds Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- ZZIZZTHXZRDOFM-XFULWGLBSA-N tamsulosin hydrochloride Chemical compound [H+].[Cl-].CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-XFULWGLBSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
- G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
- G01N24/087—Structure determination of a chemical compound, e.g. of a biomolecule such as a protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
- G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01V—GEOPHYSICS; GRAVITATIONAL MEASUREMENTS; DETECTING MASSES OR OBJECTS; TAGS
- G01V3/00—Electric or magnetic prospecting or detecting; Measuring magnetic field characteristics of the earth, e.g. declination, deviation
- G01V3/14—Electric or magnetic prospecting or detecting; Measuring magnetic field characteristics of the earth, e.g. declination, deviation operating with electron or nuclear magnetic resonance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- High Energy & Nuclear Physics (AREA)
- General Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Environmental & Geological Engineering (AREA)
- Geology (AREA)
- Remote Sensing (AREA)
- General Life Sciences & Earth Sciences (AREA)
- Geophysics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/844,124 US6043024A (en) | 1997-04-18 | 1997-04-18 | Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules |
| PCT/US1998/007907 WO1998048264A1 (en) | 1997-04-18 | 1998-04-17 | Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP0003956A2 HUP0003956A2 (en) | 2001-03-28 |
| HUP0003956A3 HUP0003956A3 (en) | 2002-04-29 |
| HU228433B1 true HU228433B1 (en) | 2013-03-28 |
Family
ID=25291882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0003956A HU228433B1 (en) | 1997-04-18 | 1998-04-17 | Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6043024A (ko) |
| EP (1) | EP0975954B2 (ko) |
| JP (1) | JP2002507277A (ko) |
| KR (1) | KR100542420B1 (ko) |
| CN (1) | CN1225648C (ko) |
| AR (1) | AR004651A1 (ko) |
| AT (1) | ATE259061T1 (ko) |
| AU (1) | AU7138098A (ko) |
| BG (1) | BG64326B1 (ko) |
| BR (1) | BR9808079A (ko) |
| CA (1) | CA2286795C (ko) |
| CO (1) | CO5060446A1 (ko) |
| CZ (1) | CZ297275B6 (ko) |
| DE (1) | DE69821475T3 (ko) |
| DK (1) | DK0975954T4 (ko) |
| ES (1) | ES2215296T5 (ko) |
| HK (1) | HK1027158A1 (ko) |
| HU (1) | HU228433B1 (ko) |
| IL (1) | IL131726A0 (ko) |
| NO (1) | NO995078L (ko) |
| NZ (1) | NZ337126A (ko) |
| PL (1) | PL194184B1 (ko) |
| PT (1) | PT975954E (ko) |
| SI (1) | SI0975954T1 (ko) |
| SK (1) | SK285411B6 (ko) |
| TR (1) | TR199902167T2 (ko) |
| TW (1) | TW574502B (ko) |
| WO (1) | WO1998048264A1 (ko) |
| ZA (1) | ZA982919B (ko) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001503646A (ja) * | 1996-03-29 | 2001-03-21 | ローレンス バークレー ナショナル ラボラトリィ | 過分極化希ガス存在下でのｎｍｒまたはｍｒｉの増強 |
| US20030143757A1 (en) * | 1997-06-13 | 2003-07-31 | Jonathan Moore | Methods for identifying drug cores |
| US6111066A (en) | 1997-09-02 | 2000-08-29 | Martek Biosciences Corporation | Peptidic molecules which have been isotopically substituted with 13 C, 15 N and 2 H in the backbone but not in the sidechains |
| US6344330B1 (en) | 1998-03-27 | 2002-02-05 | The Regents Of The University Of California | Pharmacophore recombination for the identification of small molecule drug lead compounds |
| JP2002534687A (ja) * | 1998-12-30 | 2002-10-15 | アメルシャム・パブリック・リミテッド・カンパニー | 過分極を使用したｎｍｒ分光学アッセイ |
| US6333149B1 (en) | 1999-06-04 | 2001-12-25 | Triad Biotechnology, Inc. | NMR-solve method for rapid identification of bi-ligand drug candidates |
| WO2001014886A2 (en) * | 1999-08-23 | 2001-03-01 | Polaris Pharmaceuticals, Inc. | Inhibitors of binding between proteins and macromolecular ligands |
| US6677160B1 (en) | 1999-09-29 | 2004-01-13 | Pharmacia & Upjohn Company | Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules |
| US6764858B2 (en) | 1999-09-29 | 2004-07-20 | Pharmacia & Upjohn Company | Methods for creating a compound library |
| US20010051333A1 (en) * | 2000-04-17 | 2001-12-13 | Pharmacia & Upjohn Company | Nuclear magnetic resonance methods for identifying sites in papillomavirus E2 protein |
| US7146277B2 (en) * | 2000-06-13 | 2006-12-05 | James H. Prestegard | NMR assisted design of high affinity ligands for structurally uncharacterized proteins |
| US20030165431A1 (en) * | 2000-07-13 | 2003-09-04 | The Regents Of The University Of California | Method for detecting macromolecular conformational change and binding information |
| US7061237B2 (en) * | 2000-07-13 | 2006-06-13 | The Regents Of The University Of California | Remote NMR/MRI detection of laser polarized gases |
| EP1320387B1 (en) * | 2000-09-13 | 2012-04-11 | Praecis Pharmaceuticals Incorporated | Pharmaceutical compositions for sustained delivery of peptides |
| AU1106902A (en) | 2000-09-27 | 2002-04-08 | Univ Leiden | Method for applying nmr for ligand discovery or as a drug screening tool |
| CA2432924A1 (en) * | 2000-12-21 | 2002-06-27 | Triad Therapeutics, Inc. | Sea-trosy and related methods |
| GB0031566D0 (en) * | 2000-12-22 | 2001-02-07 | Mets Ometrix | Methods for spectral analysis and their applications |
| US20030092027A1 (en) * | 2001-06-01 | 2003-05-15 | Luciano Mueller | Nuclear magnetic resonance method for identifying ligands to target compounds |
| EP1423427A2 (en) * | 2001-08-27 | 2004-06-02 | Novartis AG | Nogo receptor homologues and their use |
| US7653490B2 (en) | 2001-09-10 | 2010-01-26 | Triad Liquidating Company LLC | Nuclear magnetic resonance assembly of chemical entities |
| US20050221420A1 (en) * | 2001-10-22 | 2005-10-06 | Carmen Barske | Nogo receptor homologues and their use |
| US7037660B2 (en) * | 2001-11-06 | 2006-05-02 | Message Pharmaceuticals | Methods for detecting and quantifying binding and inhibition of binding of species to nucleic acids |
| KR100888805B1 (ko) * | 2002-06-14 | 2009-03-16 | 크리스탈지노믹스(주) | 특정 아미노산이 표지된 단백질과 1ｄ ｎｍｒ 기법을이용하여 단백질의 활성 부위에 결합하는 화합물을검색하는 방법 |
| KR100901309B1 (ko) * | 2002-06-15 | 2009-06-09 | 크리스탈지노믹스(주) | 단백질의 활성 부위에 결합하는 화합물을 선별하는 방법 |
| NO20025738D0 (no) * | 2002-11-29 | 2002-11-29 | Amersham Health As | Metode |
| CA2466792A1 (en) * | 2003-05-16 | 2004-11-16 | Affinium Pharmaceuticals, Inc. | Evaluation of spectra |
| US7595170B2 (en) * | 2004-08-05 | 2009-09-29 | Modrovich Ivan E | Apparatus and method for measuring concentrations of molecules through a barrier |
| US8933209B2 (en) | 2006-04-26 | 2015-01-13 | Abbvie Inc. | Dep2 and its uses in major depressive disorder and other related disorders |
| US20070256148A1 (en) * | 2006-04-26 | 2007-11-01 | Katz David A | DEP2 and its uses in major depressive disorder and other related disorders |
| FR2954830A1 (fr) * | 2009-12-31 | 2011-07-01 | Nmrtec | Methode d'analyse comparative par resonance magnetique nucleaire |
| CA2848520C (en) * | 2011-09-29 | 2019-11-26 | Seattle Genetics, Inc. | Intact mass determination of protein conjugated agent compounds |
| CN102507627B (zh) * | 2011-11-14 | 2014-10-01 | 中国科学院武汉物理与数学研究所 | 一种高通量筛选药物的核磁共振方法 |
| US9678185B2 (en) | 2013-03-15 | 2017-06-13 | Pepsico, Inc. | Method and apparatus for measuring physico-chemical properties using a nuclear magnetic resonance spectrometer |
| CN104198517B (zh) * | 2014-09-23 | 2017-02-08 | 中国科学院昆明植物研究所 | 联合使用不同核的一维核磁共振混合物定量方法 |
| CN104897826B (zh) * | 2015-06-16 | 2016-06-22 | 广西师范大学 | 一种用于细胞原位检测小分子化合物与靶蛋白相互作用的方法 |
| CN107328804B (zh) * | 2017-07-21 | 2019-02-05 | 中国科学院山西煤炭化学研究所 | 一种甘油加氢反应混合物的核磁共振检测方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4789832A (en) * | 1987-01-14 | 1988-12-06 | Jeol Ltd. | Three-dimensional NMR spectroscopy |
| JPH05503691A (ja) * | 1989-12-29 | 1993-06-17 | ユニバーシティ・テクノロジーズ・インターナショナル・インコーポレイテッド | アゴニストおよびアンタゴニストを含む生物学的に活性なリガンドの３次構造モデルの設計方法およびアンギオテンシンに基づいた新規合成アンタゴニスト |
| US5270163A (en) * | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5698401A (en) * | 1995-11-14 | 1997-12-16 | Abbott Laboratories | Use of nuclear magnetic resonance to identify ligands to target biomolecules |
-
1997
- 1997-04-18 US US08/844,124 patent/US6043024A/en not_active Expired - Lifetime
-
1998
- 1998-03-11 TW TW87103594A patent/TW574502B/zh not_active IP Right Cessation
- 1998-04-06 ZA ZA982919A patent/ZA982919B/xx unknown
- 1998-04-15 CO CO98020602A patent/CO5060446A1/es unknown
- 1998-04-17 SI SI9830634T patent/SI0975954T1/xx unknown
- 1998-04-17 CA CA2286795A patent/CA2286795C/en not_active Expired - Fee Related
- 1998-04-17 JP JP54622898A patent/JP2002507277A/ja active Pending
- 1998-04-17 HU HU0003956A patent/HU228433B1/hu not_active IP Right Cessation
- 1998-04-17 CN CNB988042711A patent/CN1225648C/zh not_active Expired - Fee Related
- 1998-04-17 DE DE69821475T patent/DE69821475T3/de not_active Expired - Lifetime
- 1998-04-17 PL PL98336299A patent/PL194184B1/pl unknown
- 1998-04-17 PT PT98918461T patent/PT975954E/pt unknown
- 1998-04-17 BR BR9808079-2A patent/BR9808079A/pt not_active IP Right Cessation
- 1998-04-17 DK DK98918461T patent/DK0975954T4/da active
- 1998-04-17 AT AT98918461T patent/ATE259061T1/de active
- 1998-04-17 NZ NZ337126A patent/NZ337126A/en not_active IP Right Cessation
- 1998-04-17 ES ES98918461T patent/ES2215296T5/es not_active Expired - Lifetime
- 1998-04-17 TR TR1999/02167T patent/TR199902167T2/xx unknown
- 1998-04-17 IL IL13172698A patent/IL131726A0/xx not_active IP Right Cessation
- 1998-04-17 KR KR1019997009544A patent/KR100542420B1/ko active IP Right Grant
- 1998-04-17 EP EP98918461A patent/EP0975954B2/en not_active Expired - Lifetime
- 1998-04-17 WO PCT/US1998/007907 patent/WO1998048264A1/en active IP Right Grant
- 1998-04-17 AU AU71380/98A patent/AU7138098A/en not_active Abandoned
- 1998-04-17 AR ARP980101800A patent/AR004651A1/es unknown
- 1998-04-17 CZ CZ0368399A patent/CZ297275B6/cs not_active IP Right Cessation
- 1998-04-17 SK SK1416-99A patent/SK285411B6/sk not_active IP Right Cessation
-
1999
- 1999-10-18 NO NO995078A patent/NO995078L/no not_active Application Discontinuation
- 1999-11-04 BG BG103856A patent/BG64326B1/bg unknown
-
2000
- 2000-07-28 HK HK00104759A patent/HK1027158A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU228433B1 (en) | Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules | |
| Li et al. | Alkyne-and nitrile-anchored gold nanoparticles for multiplex SERS imaging of biomarkers in cancer cells and tissues | |
| Lucas et al. | Measuring ligand‐protein binding using NMR diffusion experiments | |
| Stryer et al. | A spin-labeled hapten. | |
| Nicholson et al. | High resolution nuclear magnetic resonance spectroscopy of biological samples as an aid to drug development | |
| DE19621133A1 (de) | Bestimmungsverfahren mit oligomerisierten Rezeptoren | |
| JPH02504640A (ja) | 表面カップリング官能性を有するイットリウム、ランタニドおよびアクチニドの大環状錯体 | |
| Tengel et al. | Use of 19F NMR spectroscopy to screen chemical libraries for ligands that bind to proteins | |
| Hoesl et al. | Internal standardization of LA-ICP-MS immuno imaging via printing of universal metal spiked inks onto tissue sections | |
| DE69613146T3 (de) | Verwendung von kernspinresonanz zur bestimmung von liganden für zielbiomoleküle | |
| DE60310012T2 (de) | Verfahren, Assay und Kit zur Quantifizierung von HIV-Proteasehemmer | |
| JPH04504063A (ja) | 悪性疾病を検出する方法 | |
| US6652833B2 (en) | Functionalized active-nucleus complex sensor | |
| CN109690313A (zh) | 使用至少两种抗原检测样品中分枝杆菌物质存在的方法 | |
| Nieto | The Use of NMR to Study Transient Carbohydrate—Protein Interactions | |
| Kachooei et al. | Constructing a structural model of troponin using site-directed spin labeling: EPR and PRE-NMR | |
| CN107607711A (zh) | 铁蛋白检测试剂盒及其制备方法 | |
| AU772620B2 (en) | Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules | |
| Mason et al. | Glutathione in whole blood: a novel determination using double quantum coherence transfer proton NMR spectroscopy | |
| DE69931467T3 (de) | Neue komplexe, die vernetztes avidin enthalten, verfahren zur herstellung und analyseverfahren, das diese verwendet | |
| De Silva et al. | Optimization of time-resolved fluorescence assay for detection of Eu-DOTA-labeled ligand-receptor interactions | |
| Kuhn et al. | Illuminating the Human Metabolome: Selective Detection of Multiple Metabolites in Unaltered Biofluids via Hyperpolarisation-Enhanced NMR Spectroscopy | |
| MXPA99009558A (en) | Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules | |
| DE102015121187A1 (de) | Baukasten für ein Multiplex-Drug Discovery System mit High-Throughput Eigenschaften | |
| JPS59206763A (ja) | 生体高分子の定量法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB9A | Succession in title |
Owner name: ABBVIE INC., US Free format text: FORMER OWNER(S): ABBOTT LABORATORIES, US |
|
| MM4A | Lapse of definitive patent protection due to non-payment of fees |